Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a
Imaging services provider Radiologix reported a net loss of $2.1 million, or 10¢ per diluted share, compared with net income of $276,000, or 2¢ per diluted share for the same period last year. Income from continuing operations excluding charges and a gain on sale of operations rose, however, to $1 million, or 5¢ per diluted share, compared with $898,000, or 4¢ per diluted share in 2Q 2003. Earnings before interest, taxes, depreciation, and amortization (EBITDA) were $12.5 million for 2Q 2004, compared with $12.6 million for 2Q 2003. Adjusted EBITDA as a percentage of service fee revenue was 18.4% for the 2Q 2004, compared with 20.3% for 2Q 2003.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.